In the BioHarmony Drug Report Database
Rimegepant
Nurtec Odt (rimegepant) is a small molecule pharmaceutical. Rimegepant was first approved as Nurtec Odt on 2020-02-27. It is used to treat migraine disorders, migraine with aura, and migraine without aura in the USA. The pharmaceutical is active against calcitonin gene-related peptide type 1 receptor. Nurtec odt’s patents are valid until 2039-03-25 (FDA).
Trade Name
|
Nurtec Odt |
|---|---|
Common Name
|
rimegepant |
ChEMBL ID
|
CHEMBL2178422 |
Indication
|
migraine disorders, migraine with aura, migraine without aura |
Drug Class
|
Calcitonin gene-related peptide receptor antagonists |
Image (chem structure or protein)